Dynavax Technologies Corp DVAX
We take great care to ensure that the data presented and summarized in this overview for DYNAVAX TECHNOLOGIES CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding DVAX
View all-
Black Rock Inc. New York, NY21.9MShares$272 Million0.01% of portfolio
-
Deep Track Capital, LP Greenwich, CT12.5MShares$156 Million5.15% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.22MShares$115 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ8.33MShares$103 Million7.62% of portfolio
-
State Street Corp Boston, MA7.69MShares$95.5 Million0.0% of portfolio
-
Federated Hermes, Inc. Pittsburgh, PA5.61MShares$69.7 Million0.14% of portfolio
-
Chicago Capital, LLC5.49MShares$68.2 Million1.72% of portfolio
-
Goldman Sachs Group Inc New York, NY4.29MShares$53.3 Million0.01% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.9MShares$48.4 Million0.01% of portfolio
-
Morgan Stanley New York, NY3.08MShares$38.2 Million0.0% of portfolio
Latest Institutional Activity in DVAX
Top Purchases
Top Sells
About DVAX
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
Insider Transactions at DVAX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 31
2024
|
Francis Cano |
SELL
Open market or private sale
|
Direct |
3,615
-8.92%
|
$39,765
$11.93 P/Share
|
|
May 24
2024
|
Francis Cano |
SELL
Payment of exercise price or tax liability
|
Direct |
3,885
-8.75%
|
$42,735
$11.39 P/Share
|
|
May 24
2024
|
Francis Cano |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+14.45%
|
$37,500
$5.9 P/Share
|
|
May 23
2024
|
Julia Marie Eastland |
BUY
Grant, award, or other acquisition
|
Direct |
5,357
+25.0%
|
-
|
|
May 23
2024
|
Scott Dunseth Myers |
BUY
Grant, award, or other acquisition
|
Direct |
5,357
+17.39%
|
-
|
|
May 23
2024
|
Brent Mac Gregor |
BUY
Grant, award, or other acquisition
|
Direct |
5,357
+25.0%
|
-
|
|
May 23
2024
|
Daniel L Kisner |
BUY
Grant, award, or other acquisition
|
Direct |
5,357
+23.36%
|
-
|
|
May 23
2024
|
Peggy V Phillips |
BUY
Grant, award, or other acquisition
|
Direct |
5,357
+10.9%
|
-
|
|
May 23
2024
|
Peter R. Paradiso |
BUY
Grant, award, or other acquisition
|
Direct |
5,357
+21.93%
|
-
|
|
May 23
2024
|
Francis Cano |
BUY
Grant, award, or other acquisition
|
Direct |
5,357
+12.68%
|
-
|
|
May 23
2024
|
Elaine D Sun |
BUY
Grant, award, or other acquisition
|
Direct |
5,357
+18.18%
|
-
|
|
Mar 01
2024
|
Justin Burgess VP Finance & CAO |
SELL
Open market or private sale
|
Direct |
20,526
-67.3%
|
$246,312
$12.78 P/Share
|
|
Mar 01
2024
|
Justin Burgess VP Finance & CAO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,101
+15.75%
|
$71,010
$10.27 P/Share
|
|
Feb 16
2024
|
Justin Burgess VP Finance & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,378
-15.05%
|
$28,536
$12.41 P/Share
|
|
Feb 16
2024
|
Justin Burgess VP Finance & CAO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,667
+29.67%
|
-
|
|
Feb 15
2024
|
David F Novack President & COO |
BUY
Grant, award, or other acquisition
|
Direct |
1,207
+5.18%
|
$10,863
$9.45 P/Share
|
|
Feb 15
2024
|
Ryan Spencer CEO and Director |
BUY
Grant, award, or other acquisition
|
Direct |
402
+0.2%
|
$3,618
$9.45 P/Share
|
|
Feb 12
2024
|
David F Novack President & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,151
-13.11%
|
$37,812
$12.82 P/Share
|
|
Feb 12
2024
|
Robert Janssen SVP and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,531
-2.54%
|
$18,372
$12.82 P/Share
|
|
Feb 12
2024
|
Justin Burgess VP Finance & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,499
-21.48%
|
$29,988
$12.82 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 133K shares |
|---|---|
| Grant, award, or other acquisition | 44.5K shares |
| Payment of exercise price or tax liability | 59.4K shares |
|---|---|
| Open market or private sale | 24.1K shares |